Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Dec;76(12):1464, 1466-9.
doi: 10.1007/s00115-005-1939-0.

[The neurophysiology of cataplexy]

[Article in German]
Affiliations
Review

[The neurophysiology of cataplexy]

[Article in German]
G Mayer. Nervenarzt. 2005 Dec.

Abstract

Cataplexy and excessive daytime sleepiness are the leading symptoms of narcolepsy. Electrophysiological studies in humans do not show a clear association between cataplexy and rapid eye movement (REM) sleep. Even a decrement of the H reflex is not specific for cataplexy and may be caused by unspecific triggers such as coughing. Cholinomimetics, which may induce status cataplecticus, do not influence REM sleep, thus evidencing a REM-independent mechanism. Recent studies demonstrate a lack of the neuropeptide hypocretin in the CSF of narcoleptics. Hypocretin controls wakefulness and the motor and autonomous systems. In hypocretin-1 and -2 knockout mice, sudden stops of motor activity could be observed in emotional situations that were accompanied by sudden shifts from wakefulness to REM sleep and could be terminated by application of anticataplectic medication. The lack of hypocretin not only causes a noradrenergic-cholinergic imbalance in the midbrain but also influences motoneurons directly by juxtacellular hypocretin-containing membranes. Intravenous application of hypocretin in a dog with hypocretin deficiency in the CSF caused a dose-dependent decrease of cataplexies. An understanding of the neuronal mechanisms responsible for cataplexies is essential for the development of new anticataplectic medications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Neurophysiol. 2002 May;87(5):2480-9 - PubMed
    1. Neuroscience. 1994 Apr;59(3):511-22 - PubMed
    1. Rev Neurol (Paris). 1957 Nov;97(5):388-93 - PubMed
    1. Clin Neurophysiol. 2000 Sep;111 Suppl 2:S120-8 - PubMed
    1. Neurology. 2002 Dec 24;59(12):1988-91 - PubMed

LinkOut - more resources